ChinaDrugStatus
Commercial Health Insurance Innovative Drug List (商业健康保险创新药品目录)

2026 Commercial Insurance Innovative Drug List

Published Nov 14, 2026 alongside the 2026 NRDL (28 total drugs in the full 2026 PDF vs 19 in 2025). This page highlights verified launch-sample additions, indication expansions, and 2025 exits/graduations into basic NRDL.

Export CSV

Policy scope note: Inclusion in the NHSA Commercial Health Insurance Innovative Drug List indicates national catalog listing for commercial insurer reference (basic medical insurance funds do not reimburse these drugs). Actual patient reimbursement depends on the specific commercial health insurance policy contract.

2026 Commercial List — Verified Sample Additions & Expansions (4)

Effective Jan 1, 2027
No. & BrandGeneric NameMAH & Authorized EntityListed Indication ScopeAgreement & StatusSource
#13
源瑞达
Indication Expanded
Inaticabtagene autoleucel
纳基奥仑赛注射液
Juventas Cell Therapy Ltd.
Authorized: 合源生物科技股份有限公司

Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.

Show Chinese catalog text

本品适用于成人复发或难治性B细胞急性淋巴细胞白血病。本品适用于经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤,包括:弥漫大B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的大B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤。

Jan 1, 2026 – Dec 31, 2027
Announced · Effective Jan 1, 2027
NHSA · PDF p.3
Verified 2026-11-20
#24
Wainua / 万诺维
Newly Added 2026
Eplontersen sodium
依普隆特生钠注射液
AstraZeneca AB
Authorized: 阿斯利康(无锡)贸易有限公司

Adult patients with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).

Show Chinese catalog text

本品适用于治疗成人遗传性转甲状腺素蛋白淀粉样变性多发性神经病(ATTRv-PN)患者。

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-20
#25
Qalsody / 凯盛迪
Newly Added 2026
Tofersen
托夫生注射液
Biogen MA Inc.
Authorized: 渤健生物科技(上海)有限公司

Adult patients with amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Show Chinese catalog text

本品用于治疗携带超氧化物歧化酶1(SOD1)基因突变的肌萎缩侧索硬化(ALS)成人患者。

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.4
Verified 2026-11-20
#28
Pluvicto / 派威妥
Newly Added 2026
Lutetium (177Lu) vipivotide tetraxetan
镥[177Lu]特昔维匹肽注射液
Novartis Pharma Schweiz AG
Authorized: 诺华医药科技(浙江)有限公司

Adult PSMA-positive mCRPC: (1) After progression on ARPI and eligible to delay chemotherapy; (2) After progression on ARPI and taxane-based chemotherapy.

Show Chinese catalog text

本品适用于以下成人患者:1.既往接受雄激素受体通路抑制剂(ARPI)后疾病进展且适合延迟化疗的前列腺特异性膜抗原(PSMA)阳性转移性去势抵抗性前列腺癌(mCRPC);2.既往接受雄激素受体通路抑制和紫杉类化疗后疾病进展的PSMA阳性mCRPC。

Jan 1, 2027 – Dec 31, 2028
Announced · Effective Jan 1, 2027
NHSA · PDF p.5
Verified 2026-11-20

2025 Commercial List Entries Not Carried Into 2026 (3)

Verified by diffing the official 2025 Commercial List PDF (19 drugs) against the 2026 Commercial List PDF (28 drugs). Two therapies graduated directly into the 2026 basic NRDL.

2025 No. & BrandGeneric Name2026 OutcomeMAH2025 Source
2025 #2
海普益
Sapropterin dihydrochloride
盐酸沙丙蝶呤片
Graduated to 2026 Basic NRDL (#42)

Reimbursed under basic medical insurance effective Jan 1, 2027.

Shandong New Time Pharmaceutical Co., Ltd.NHSA · PDF p.2
2025 #12
Carteyva / 倍诺达
Relmacabtagene autoleucel
瑞基奥仑赛注射液
Graduated to 2026 Basic NRDL (#297)

Reimbursed under basic medical insurance effective Jan 1, 2027.

JW Therapeutics (Shanghai) Co., Ltd.NHSA · PDF p.4
2025 #16
Tazverik / 达唯珂
Tazemetostat hydrobromide
氢溴酸他泽司他片
Omitted from 2026 Commercial List

Not listed in 2026 Commercial List or 2026 NRDL.

Epizyme, Inc.NHSA · PDF p.4